Kymera Therapeutics, Inc.

NASDAQ:KYMR

Biotechnology

Healthcare
$121.13 +1.67%

+$1.50 today

Market cap
$10.34B
Beta
2.03
P/E (TTM)
-28.3
EPS (TTM)
-$3.23
52W Low $36.65High $103.00

Volume 0.68M

Average 0.58M

KYMR Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Kymera Therapeutics, Inc.NASDAQ: KYMR

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of $21.13M rose 19.7% year over year, ahead of the +15.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.8% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.

Context

  • Selling, general & admin amounted to 174.0% of revenue in FY2025, up 39.0 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 17 analysts of $103.85M (+52.3%) for the fiscal year ending Dec 2026, a step up from the +7.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$21.13M+3.8% QoQ
Last fiscal yearDec 2025
$68.2M+7.3% YoY
LTMJun 2026
$75.77M+15.3% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.7%-80.3%-100.0 pp
1 year+7.3%+52.3%+44.9 pp
3-year CAGR+15.9%-15.0%-30.9 pp
5-year CAGR+39.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
68.2M USD
Year-over-year change
+7.3%
4-year CAGR
+17.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How KYMR compares with its peers on the latest reported figures

  • KYMR's LTM Jun 2026 selling, general & admin of $75.77M is the 3rd highest of the 5 companies compared; the peer median is $58.03M.
  • Its year-over-year change of +15.3% is the 2nd highest of 5, against a peer median of -4.0%.
  • Selling, general & admin amounts to 72.2% of revenue for KYMR, versus a peer median of 92.4%.
KYMR Competitors Peer median
Selling, General & Admin for KYMR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARVNArvinas, Inc.LTM Mar 2026$86.5M -47.9%+3.9%96.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$78.21M +57.0%+11.6%11.1%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$75.77M +15.3%+15.9%72.2%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$37.85M +8.5%+10.0%88.1%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$34.4M -16.4%-5.4%98.7%
Peer median (excluding KYMR) $58.03M-4.0%+7.0%92.4%

Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue72.83M46.83M78.59M47.07M39.2M
Cost of Revenue00000
Gross Profit72.83M46.83M78.59M47.07M39.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development137.02M164.25M189.08M240.25M316.6M
Selling, General & Admin36.35M43.83M55.04M63.53M68.2M
Operating Expenses173.36M208.08M244.12M308.71M388.6M
Depreciation & Amortization2.4M2.98M3.57M7.37M8.31M
EBITDA(97.65M)(151.66M)(143.2M)(216.24M)(303.06M)
EBITDA Margin-134.1%-323.9%-182.2%-459.4%-773.1%
Operating Income(100.53M)(161.26M)(165.53M)(261.64M)(349.4M)
Operating Margin-138.0%-344.4%-210.6%-555.8%-891.3%
Interest Income488K6.62M18.76M38.03M38.03M
Interest Expense175K176K196K249K249K
Other Income / Expenses313K6.45M18.57M37.78M37.78M
Income Before Tax(100.22M)(154.81M)(146.96M)(223.86M)(311.62M)
Pre-Tax Margin-137.6%-330.6%-187.0%-475.6%-795.0%
Income Tax Expense00000
Net Income(100.22M)(154.81M)(146.96M)(223.86M)(311.4M)
Net Margin-137.6%-330.6%-187.0%-475.6%-794.4%
EPS (Basic)(2.09)(2.87)(2.52)(2.98)(3.69)
EPS (Diluted)(2.09)(2.87)(2.52)(2.98)(3.69)
Weighted Avg Shares47.99M53.93M58.37M75.04M84.39M
Weighted Avg Shares (Diluted)47.99M53.93M58.37M75.04M84.39M

Kymera Therapeutics, Inc.

NASDAQ:KYMR

Intrinsic Alpha fair value

Locked

Current Price

$121.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.